(Circulation. 1999;99:2055-2057.)
© 1999 American Heart Association, Inc.
Current Perspective |
Trends in Antihypertensive Drug Advertising, 1985–1996
From the Institute for Health Policy and General Medicine Division, Massachusetts General Hospital, Medical Services and Department of Medicine, Harvard Medical School, Boston, Mass.
Background—Over the past decade, calcium channel blockers (CCBs) and ACE inhibitors have been used increasingly in the treatment of hypertension. In contrast, ß-blocker and diuretic use has decreased. It has been suggested that pharmaceutical marketing has influenced these prescribing patterns. No objective analysis of advertising for antihypertensive therapies exists, however.
Methods and Results—We reviewed the January, April, July, and
October issues of the New England Journal of Medicine
from 1985 to 1996 (210 issues). The intensity of drug promotion was
measured as the proportion of advertising pages used to promote a given
medication. Statistical analyses used the 
2 test
for trend. Advertising for CCBs increased from 4.6% of advertising
pages in 1985 to 26.9% in 1996, while advertising for ß-blockers
(12.4% in 1985 to 0% in 1996) and diuretics (4.2% to 0%)
decreased (all P<0.0001). A nonsignificant increase was
observed in advertising for ACE inhibitors (3.5% to 4.3%,
P=0.17). Although the total number of drug advertising
pages per issue decreased from 60 pages in 1985 to 42 pages in 1996
(P<0.001), the number of pages devoted to calcium
channel blocker advertisements nearly quadrupled.
Conclusions—Increasing promotion of CCBs has mirrored trends in physician prescribing. An association between advertising and prescribing patterns could explain why CCBs have supplanted better-substantiated therapies for hypertension.
Key Words: hypertension • practice patterns • drug therapy • advertising
This article has been cited by other articles:
 |
|
 |
|
  Y. Wu, R. Huxley, L. Li, V. Anna, G. Xie, C. Yao, M. Woodward, X. Li, J. Chalmers, R. Gao, et al. Prevalence, Awareness, Treatment, and Control of Hypertension in China: Data from the China National Nutrition and Health Survey 2002 Circulation, December 16, 2008; 118(25): 2679 - 2686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Mozaffarian, P. W.F. Wilson, and W. B. Kannel Beyond Established and Novel Risk Factors: Lifestyle Risk Factors for Cardiovascular Disease Circulation, June 10, 2008; 117(23): 3031 - 3038. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ma, K.-V. Lee, and R. S. Stafford Changes in Antihypertensive Prescribing During US Outpatient Visits for Uncomplicated Hypertension Between 1993 and 2004 Hypertension, November 1, 2006; 48(5): 846 - 852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Stafford, V. Monti, C. D. Furberg, and J. Ma Long-Term and Short-Term Changes in Antihypertensive Prescribing by Office-Based Physicians in the United States Hypertension, August 1, 2006; 48(2): 213 - 218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R.C. Campbell, K. Tu, R. Brant, M. Duong-Hua, F. A. McAlister, and for the Canadian Hypertension Education Program Ou The Impact of the Canadian Hypertension Education Program on Antihypertensive Prescribing Trends Hypertension, January 1, 2006; 47(1): 22 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Majumdar, E. A. Almasi, and R. S. Stafford Promotion and Prescribing of Hormone Therapy After Report of Harm by the Women's Health Initiative JAMA, October 27, 2004; 292(16): 1983 - 1988. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Husain Pharmaceutical influence and psychiatrists: an introspection The British Journal of Psychiatry, October 1, 2004; 185(4): 354 - 354. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Tu, M. M. Mamdani, R. M. Jacka, N. J. Forde, D. M. Rothwell, and J. V. Tu The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario Can. Med. Assoc. J., March 4, 2003; 168(5): 553 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J Andersson, G. Lindberg, and M. Troein What shapes GPs' work with depressed patients? A qualitative interview study Fam. Pract., December 1, 2002; 19(6): 623 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Psaty, T. A. Manolio, N. L. Smith, S. R. Heckbert, J. S. Gottdiener, G. L. Burke, J. Weissfeld, P. Enright, T. Lumley, N. Powe, et al. Time Trends in High Blood Pressure Control and the Use of Antihypertensive Medications in Older Adults: The Cardiovascular Health Study Arch Intern Med, November 11, 2002; 162(20): 2325 - 2332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bourgault, B. Rainville, and S. Suissa Antihypertensive Drug Therapy in Saskatchewan: Patterns of Use and Determinants in Hypertension Arch Intern Med, August 13, 2001; 161(15): 1873 - 1879. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Opie, T. J. Wang, J. C. Ausiello, and R. S. Stafford Trends in Antihypertensive Drug Treatment Response Circulation, May 30, 2000; 101 (21): e209 - e209. [Full Text] [PDF]
|
|
|
|
|
|
F. A. McAlister The treatment of hypertension in Canada: Are we making progress? Can. Med. Assoc. J., September 1, 1999; 161(6): 713 - 714. [Full Text] [PDF]
|
|